Clinical trials: Stage III Skin Cancer
Breast Cancer
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
A study to compare the efficacy, safety and immunogenicity of Leucostim® to those of Neupogen® in patients with breast cancer intended to be treated with TAC regimen as a myelosuppressive chemotherapy.
- Trial name
- NCT03343145
- Testing
- Leucostim 5µg/kg/day, Neupogen 5µg/kg/day
- Where
- Indonesia
- Volunteers
- 143 people
- Sponsor
- Dong-A ST Co., Ltd.
Secondary (AA) Amyloidosis, Rheumatoid Arthritis
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and…
- Conditions
- Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome
- Trial name
- NCT00035334
- Testing
- NC-503 (Anti-amyloidotic (AA) Agent)
- Where
- 26 sites in United States, Finland and 10 more
- Volunteers
- 150 people
- Sponsor
- Bellus Health Inc. - a GSK company
Breast Cancer
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with combinations of drugs may kill more tumor cells.
- Trial name
- NCT00002509
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Sponsor
- Temple University
Breast Cancer
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00499681
- Testing
- lapatinib ditosylate, letrozole
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00754845
- Testing
- letrozole
- Where
- 43 sites in Canada, United Kingdom
- Volunteers
- 1,918 people
- Sponsor
- Canadian Cancer Trials Group
Cancer Survivor, Healthy Subject
Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin
This randomized pilot clinical trial studies how well survivorship care plan works in promoting technology-based physical activity in breast or colorectal cancer survivors in Wisconsin.
- Conditions
- Cancer Survivor, Healthy Subject, Stage I Colorectal Cancer, Stage IA Breast Cancer
- Trial name
- NCT02677389
- Testing
- Educational Intervention, Internet-Based Intervention, Monitoring Device
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00943410
- Testing
- external beam radiation therapy, Herceptin
- Volunteers
- 19 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Our study evaluates the use of Laser-Assisted Immunotherapy (LIT) plus placebo and LIT plus low-dose cyclophosphamide versus that of Standard of Care in patients presenting with Stage IIIA, IIIB or IV breast cancer.
- Conditions
- Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB, Breast Cancer Stage IV
- Trial name
- NCT03202446
- Testing
- 1% Glycated Chitosan, Photothermal Laser, Cyclophosphamide
- Where
- 4 sites in Peru
- Volunteers
- 18 people
- Sponsor
- Eske Corporation S.A.C
Male Breast Cancer, Stage II Breast Cancer
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes.
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00119262
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with…
- Trial name
- PARTNER (NCT03150576)
- Testing
- Olaparib, Paclitaxel and Carboplatin
- Where
- 30 sites in United Kingdom
- Volunteers
- 780 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
The study is being conducted to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma
- Trial name
- NCT01953588
- Testing
- fulvestrant, anastrozole
- Where
- 860 sites in United States, Puerto Rico
- Volunteers
- 1,473 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
BRF113683 is a Phase III, randomized, open-label study comparing the efficacy, safety, and tolerability of GSK2118436 to dacarbazine (DTIC), in subjects with BRAF mutant advanced (Stage III) or metastatic (Stage IV) melanoma.
- Trial name
- NCT01227889
- Testing
- GSK2118436, Dacarbazine (DTIC)
- Where
- 94 sites in United States, Australia and 10 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Hypofractionated Radiotherapy After Breast Reconstruction for Breast Cancer
This study aims to evaluate the efficacy and safety of hyperfractionated radiotherapy (40Gy/15 fractions) compared to conventional fractionated radiotherapy (50Gy/25 fractions) in breast cancer patients undergoing breast…
- Trial name
- NCT07831889
- Testing
- Whole-dose radiotherapy, Conventional fractionated radiotherapy
- Volunteers
- 960 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Melanoma (Skin)
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells.
- Trial name
- NCT00002535
- Testing
- aldesleukin, lymphokine-activated killer cells, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Sponsor
- St. Luke's Medical Center
Breast Cancer
ICI 182780 in Treating Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 may fight breast cancer by blocking the activity of estrogen in the tumor cells.
- Trial name
- NCT00012025
- Testing
- fulvestrant
- Where
- 25 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Melanoma (Skin)
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
Prospective non-interventional study of clinical outcomes and biomarkers in patients with stage 0-IV skin melanoma in real clinical practice
- Conditions
- Melanoma, Melanoma (Skin), Melanoma, Uveal, Melanoma Stage IV
- Trial name
- ISABELLA (NCT05402059)
- Testing
- surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
- Where
- Russia
- Volunteers
- 1,570 people
- Sponsor
- MelanomaPRO, Russia
Breast Neoplasms
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
This is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage II-III HR…
- Trial name
- NCT05253066
- Testing
- Chidamide combined with exemestane (+/- goserelin), Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
- Volunteers
- 130 people
- Sponsor
- Shengjing Hospital
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
This clinical trial studies how well ultrasound/photoacoustic/elasticity (US/PA/E) imaging works for early identification of tumor response in patients with stage II-III triple-negative breast cancer receiving immunotherapy and…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07862751
- Testing
- Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.